Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Common Equity (2016 - 2025)

United Therapeutics (UTHR) has disclosed Common Equity for 17 consecutive years, with $7.1 billion as the latest value for Q4 2025.

  • Quarterly Common Equity rose 10.12% to $7.1 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.1 billion through Dec 2025, up 10.12% year-over-year, with the annual reading at $7.1 billion for FY2025, 10.12% up from the prior year.
  • Common Equity hit $7.1 billion in Q4 2025 for United Therapeutics, up from $6.6 billion in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $7.2 billion in Q2 2025 to a low of $3.4 billion in Q1 2021.
  • Historically, Common Equity has averaged $5.3 billion across 5 years, with a median of $5.4 billion in 2023.
  • Biggest five-year swings in Common Equity: grew 4.19% in 2024 and later increased 27.52% in 2025.
  • Year by year, Common Equity stood at $4.0 billion in 2021, then rose by 21.16% to $4.8 billion in 2022, then rose by 24.77% to $6.0 billion in 2023, then grew by 7.67% to $6.4 billion in 2024, then grew by 10.12% to $7.1 billion in 2025.
  • Business Quant data shows Common Equity for UTHR at $7.1 billion in Q4 2025, $6.6 billion in Q3 2025, and $7.2 billion in Q2 2025.